ITGB1 and irritable bowel syndrome: The authors were able to target a plethora of cell markers including CD44, CD34, CD3, CD4, CD25, CD29, Ly6C and Itgb7, and treat models of inflammatory bowel syndrome (IBS) and disseminated bone marrow mantle cell lymphoma by targeting siRNA to Ly6C and CD29, respectively.